94 filings
Page 2 of 5
8-K
hd8 64elr
8 Feb 22
Results of Operations and Financial Condition
1:44pm
8-K
yuzy0r3q9j
22 Nov 21
Results of Operations and Financial Condition
4:05pm
8-K
c446z6s6
23 Aug 21
Departure of Directors or Certain Officers
4:01pm
8-K
iigzz79zu
5 Aug 21
Results of Operations and Financial Condition
4:03pm
8-K
uklhlhmuv
16 Jul 21
Departure of Directors or Certain Officers
4:06pm
8-K
h2kqg4nllkp6odshqvm3
6 May 21
Results of Operations and Financial Condition
4:03pm
8-K
evx xr4sm6mw
5 Mar 21
Departure of Directors or Certain Officers
4:00pm
8-K
f7b6pniiyoq23lgmxn02
8 Feb 21
Results of Operations and Financial Condition
4:05pm
8-K
p68sc myx
5 Feb 21
Other Events
4:31pm
8-K
1bnhdqtma50rttn
4 Dec 20
Departure of Directors or Certain Officers
4:00pm
8-K
eh3ur00 ga3fnqhbhf
23 Nov 20
Results of Operations and Financial Condition
4:05pm
8-K
orsmr efgg1
4 Aug 20
Results of Operations and Financial Condition
4:16pm
8-K
z7xd96uj
30 Jun 20
Departure of Directors or Certain Officers
4:00pm
8-K
2t35avmyoq owv76t2px
6 May 20
Results of Operations and Financial Condition
4:09pm
8-K
bv8qdpfs hgop7
2 Mar 20
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
6v23f 084c
6 Feb 20
Positive results from part 1 of the Phase 1a/b clinical study ofEDP-514 in healthy subjects
4:14pm
8-K
4kjf4rbj w703xv5o
21 Nov 19
Results of Operations and Financial Condition
4:05pm
8-K
q3uffg3smc1mmsag
6 Aug 19
Royalty revenue for the quarter was $44.4 million
4:06pm
8-K
js6t cpoae2d88
7 May 19
Data from Phase 2a RSV program anticipated mid-2019 and Phase 2a NASH program by the end of third quarter of calendar 2019
4:04pm
8-K/A
qhv0wzb852uqxy8pp5bh
7 Mar 19
Departure of Directors or Certain Officers
4:15pm